IL-5 recombinant protein
- Known as:
- Interleukin-5 Rec. protein
- Catalog number:
- BRP1047
- Product Quantity:
- 100 μg
- Category:
- -
- Supplier:
- Biospect
- Gene target:
- IL-5 recombinant protein
Related genes to: IL-5 recombinant protein
- Gene:
- CSF2RB NIH gene
- Name:
- colony stimulating factor 2 receptor beta common subunit
- Previous symbol:
- IL3RB
- Synonyms:
- IL5RB, CD131, betaGMR
- Chromosome:
- 22q12.3
- Locus Type:
- gene with protein product
- Date approved:
- 1991-08-07
- Date modifiied:
- 2017-07-12
- Gene:
- IL5 NIH gene
- Name:
- interleukin 5
- Previous symbol:
- -
- Synonyms:
- IL-5, EDF, TRF
- Chromosome:
- 5q31.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2015-07-06
- Gene:
- IL5RA NIH gene
- Name:
- interleukin 5 receptor subunit alpha
- Previous symbol:
- IL5R
- Synonyms:
- CDw125, CD125
- Chromosome:
- 3p26.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-18
- Date modifiied:
- 2016-10-11
- Gene:
- LRR1 NIH gene
- Name:
- leucine rich repeat protein 1
- Previous symbol:
- PPIL5
- Synonyms:
- MGC20689, LRR-1
- Chromosome:
- 14q21.3
- Locus Type:
- gene with protein product
- Date approved:
- 2002-11-20
- Date modifiied:
- 2014-11-18
Related products to: IL-5 recombinant protein
Related articles to: IL-5 recombinant protein
- Lymphocyte variant hypereosinophilic syndrome (L-HES) is a rare disorder characterized by immunophenotypically abnormal T lymphocytes that produce excessive eosinophilopoietic cytokines, such as interleukin 5 (IL-5). Clinically, patients with L-HES can present with manifestations involving multiple organ systems, most commonly cutaneous lesions; however, isolated single-organ involvement excluding the skin is less common. The optimal treatment for L-HES remains poorly defined. Corticosteroids (CS) are often used as first-line therapy, while other agents - such as interferon (IFN- ), anti-IL-5 monoclonal antibodies, cyclosporine, and mycophenolate - are also employed in steroid- refractory cases, although no standardized treatment consensus has been established. Here, we report a rare case of L-HES presenting severe eosinophilic pneumonia (EP) as the sole manifestation. After experiencing relapses during treatment with CS and IFN- , the patient achieved a complete and favorable clinical response following initiation of low-dose mepolizumab - an anti-IL-5 monoclonal antibody - suggesting that mepolizumab may represent an effective therapeutic option for patients with L-HES complicated by EP. - Source: PubMed
Publication date: 2026/03/13
Wang YubinTao YuhanMao Hui - Intrauterine contraceptives (IUCs) are effective, but effects on genital inflammation among women living with HIV (WLHIV) by antiretroviral therapy (ART) use are unclear. We evaluated the longitudinal effects of copper IUC (CLIUC) and the levonorgestrel intrauterine system (LNGLIUS) on cervicovaginal cytokine profiles in a secondary analysis of a randomized trial ( NCT01721798 , 2013-2016). - Source: PubMed
Publication date: 2026/05/26
Happel Anna-UrsulaPassmore Jo-Ann SSinkala MusalulaJaumdally Shameem ZGamieldien HoyamHu Nai-ChungLangwenya NontokozoJones Heidi EHoover Donald RMyer LandonTodd Catherine S - Despite known links between inflammation and Alzheimer's disease (AD), little is understood about how inflammatory processes vary across racial/ethnic and sex groups, particularly in relation to the major genetic risk factor apolipoprotein E ε4 (APOE4), whether these differences contribute to AD disparities among understudied Hispanics. - Source: PubMed
Publication date: 2026/05/14
Contreras J AOrtega N EHayes C APa J - Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis characterized by asthma, chronic rhinosinusitis with nasal polyps, eosinophil-driven tissue inflammation, and necrotizing small- to medium-sized vessel vasculitis. Myeloperoxidase - Anti-Neutrophil Cytoplasmic Antibody (MPO-ANCA) is detectable in approximately 30%-40% of patients, and ANCA-positive and ANCA-negative diseases exhibit distinct yet overlapping clinical patterns. Type 2 immune responses are predominant, with interleukin-5 (IL-5) driving eosinophil differentiation and survival, and IL-4 and IL-13 promoting eosinophil recruitment and IgE-associated pathways. Activated eosinophils contribute to tissue injury through degranulation and eosinophil extracellular trap formation (EETosis). Glucocorticoids remain the foundation of therapy, but they are often insufficient to achieve a sustained remission as monotherapy. Conventional immunosuppressants are used for severe disease, and B-cell-targeted therapy may be considered for selected vasculitic presentations. Biological agents targeting the IL-5/IL-5 receptor axis have been shown to prolong remission, reduced relapse risk, and enabled glucocorticoid sparing. However, some patients remain symptomatic, and reliable biomarkers to guide individualized therapy are lacking. Ongoing research focuses on biomarker panels and cell-free DNA to clarify the role of EETosis and define molecular endotypes to support precision-medicine approaches. - Source: PubMed
Publication date: 2026/06/04
Hasegawa RyoHizuka KeinosukeSaga AkikoHikichi HarukaMoritoki YukiUeki Shigeharu - Eosinophilic esophagitis (EoE) is a chronic, antigen-driven inflammatory disease characterized by esophageal dysfunction and tissue remodeling. Despite increasing prevalence, its pathogenesis remains incompletely understood. This review aims to systematically synthesize current evidence on the immunological, genetic, epithelial, and extracellular matrix mechanisms driving EoE. The goal is to identify upstream molecular targets and biomarkers to support precision medicine approaches. - Source: PubMed
Publication date: 2026/06/03
Lachowicz JoannaDi Petrillo AmaliaFloris SoniaFavale AgneseLutzu NicolaOnali SaraFantini Massimo Claudio